Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD74 | P04233 | 1/20 | 0.64 |
| ▸ | MIF | P14174 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | LPO | P22079 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819982 | 0.87 | TUBB4A (0.57) | CD74MIFMEN1KMT2AGPR55 | |
| SCHEMBL19813139 | 0.84 | CD74 (0.62) | CD74MIFMEN1KMT2AGPR55 | |
| SCHEMBL16401284 | 0.81 | CD74 (0.60) | CD74MIFMEN1KMT2AGPR55 | |
| SCHEMBL12219083 | 0.81 | MEN1 (0.64) | MEN1KMT2ACMA1KDM4EALDH1A1 | |
| SCHEMBL29275461 | 0.80 | CD74 (0.81) | CD74MIFMEN1KMT2AGPR55 | |
| SCHEMBL30991876 | 0.80 | CD74 (0.81) | CD74MIFMEN1KMT2AGPR55 | |
| SCHEMBL16097875 | 0.80 | HDAC1 (0.51) | CD74MIFMEN1KMT2ACYP19A1 | |
| SCHEMBL17336967 | 0.79 | CD74 (0.64) | CD74MIFMEN1KMT2AGPR55 | |
| SCHEMBL9290483 | 0.79 | CYP19A1 (0.61) | SIGMAR1ALDH1A1CYP19A1 | |
| SCHEMBL25055361 | 0.78 | CD74 (1.00) | CD74MIFMEN1KMT2AGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-8729270-B2 | Anti-cancer compounds, synthesis thereof, and methods of using same | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2014-05-20 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289704-A1 | ANTI-CANCER COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING SAME | MCL1, BRDT, GLS | CD74 4594/4885MIF 2789/4885MEN1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.